{"protocolSection": {"identificationModule": {"nctId": "NCT04730258", "orgStudyIdInfo": {"id": "TWT-202"}, "organization": {"fullName": "Treadwell Therapeutics, Inc", "class": "INDUSTRY"}, "briefTitle": "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML", "officialTitle": "Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML", "acronym": "TWT-202"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Treadwell Therapeutics, Inc", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.", "detailedDescription": "This study will be evaluating the safety and tolerability of CFI-400945 in subjects with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia. The study is designed to build on encouraging data from another study and to obtain further safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) data of CFI-400945."}, "conditionsModule": {"conditions": ["Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "AML", "MDS", "CMML"], "keywords": ["Polo-like kinase 4", "PLK4", "serine/threonine kinase Polo-like kinase 4", "CFI-400945", "945", "Polo-Like Kinase 4 inhibitors/antagonists", "hematologic malignancies", "PLK-4", "UHN", "University Health Network", "Treadwell", "Treadwell Therapeutics", "Treadwell Tx"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SEQUENTIAL", "interventionModelDescription": "Dose escalation and expansion for monotherapy and combination arms with azacitidine", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 72, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "1A: Monotherapy escalation and expansion", "type": "EXPERIMENTAL", "description": "Dose escalation and expansion arm with CFI-400945", "interventionNames": ["Drug: CFI-400945"]}, {"label": "2A: Combination escalation and expansion", "type": "EXPERIMENTAL", "description": "Dose escalation and expansion arm with CFI-400945 and azacitidine", "interventionNames": ["Drug: CFI-400945", "Drug: Azacitidine"]}], "interventions": [{"type": "DRUG", "name": "CFI-400945", "description": "The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.", "armGroupLabels": ["1A: Monotherapy escalation and expansion", "2A: Combination escalation and expansion"], "otherNames": ["CFI-400945 fumarate", "945", "400945"]}, {"type": "DRUG", "name": "Azacitidine", "description": "Azacitidine will be given at its labeled dose and schedule", "armGroupLabels": ["2A: Combination escalation and expansion"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients must be \\>18 years of age\n2. For Parts 1A and 1B, the following malignancy types will be included:\n\n   1. Relapsed or refractory AML.\n   2. MDS, after prior hypomethylating agents.\n   3. CMML, with progressive disease/lack of response after hypomethylating agents\n\n   For Parts 1A and 1B, Patients may have relapsed or refractory disease.\n3. For Parts 2A and 2B, the following malignancy types will be included:\n\n   1. Relapsed or Refractory AML.\n   2. MDS patients should be limited to high risk disease\n   3. MDS or CMML should be previously untreated and patients with AML may have relapsed or refractory disease;\n4. Have clinically acceptable laboratory screening results (i.e., clinical chemistry, hematology, and urinalysis) within certain limits per protocol.\n5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n1. Patients who have received investigational therapy, radiotherapy, immunotherapy, monoclonal antibodies, or chemotherapy within 14 days or 5 half-lives (whichever is shorter)\n2. Allogeneic or autologous transplant for AML with infusion of stem cells within 90 days before Cycle 1 Day 1, or on active immunosuppressive therapy for graft-versus-host disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day 1.\n3. Any Grade \u2265 2 persistent non-hematological toxicity related to allogeneic transplant, such as those requiring systemic immunosuppressive therapy.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Treadwell Therapeutics Clinical Trials", "role": "CONTACT", "phone": "+1-416-455-7510", "email": "clinicaltrials@treadwelltx.com"}], "overallOfficials": [{"name": "Gautam Borthakur, MD", "affiliation": "The University of Texas MD Anderson Cancer Centre", "role": "PRINCIPAL_INVESTIGATOR"}]}}, "hasResults": false}